Bispecific Inhibition

The next generation of HER2-targeted antibodies is bispecific

Bispecific antibodies are dual targeted and may eliminate tumor cells without engaging T cells1

Multiple types of antibodies can be utilized for targeted treatment, including monoclonal antibodies and multiple bispecifics. However, not all bispecific antibodies are the same.2

Dual-targeted bispecific antibodies

Dual-targeted bispecific antibodies may work in a novel way: by binding to 2 separate targets to elicit tumor cell death in multiple ways, without engaging T cells.1

See how dual-targeted antibodies work differently from T-cell engagers and monoclonal antibodies:

T-cell engagers

Bispecific T-cell engagers bind to a target on a T cell and a target on the cancer cell to induce antitumor effects.3

Monoclonal antibodies

Monoclonal antibodies are a common formation. These antibodies target a single site on a receptor to induce antitumor activity.2

Preclinical studies suggest dual HER2-targeted bispecific antibodies may be able to enhance:

HER2 Signal Blockade

Breaks signal transmission to slow growth4

NON–T-CELL-MEDIATED IMMUNE EFFECTS

Recruit other immune cells to destroy and eliminate tumor cells1,5

HER2 internalization

Initiates receptor degradation1,5

Dual-targeted bispecific antibodies can cause tumor cell death in multiple ways without engaging T cells.1

DUAL HER2-TARGETED BISPECIFIC ANTIBODIES COULD CHANGE THE GI CANCER LANDSCAPE6

BACK: Testing for HER2
Cell Cell

GI=gastrointestinal; HER2=human epidermal growth factor receptor 2.

References

1. Niquille DL, Fitzgerald KM, Gera N. Biparatopic antibodies: therapeutic applications and prospects. MAbs. 2024;16(1):2310890. doi:10.1080/19420862.2024.2310890 2. Fine J, Meksiriporn B, Tan J, Spangler JB. Mechanism-driven design of multispecific antibodies for targeted disease treatment. Annu Rev Chem Biomol Eng. doi:10.1146/annurev-chembioeng-100522-102155 3. Tian Z, Liu M, Zhang Y, Wang X. Bispecific T-cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14(1):75. doi:10.1186/s13045-021-01084-4 4. Ma J, Mo Y, Tang M, et al. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616. doi:10.3389/fimmu.2021.626616 5. Leyton JV. Improving receptor-mediated intracellular access and accumulation of antibody therapeutics—the tale of HER2. Antibodies. 2020;9(3):32. doi:10.3390/antib9030032 6. Liu X, Fan X, Gao X, Hu W, Sun P. Leveraging HER2-targeted biparatopic antibodies in solid tumors. Pharmacol Res. 2025;214:107687. doi:10.1016/j.phrs.2025.107687